Pomalidomide-PEG3-C2-NH2 hydrochloride is primarily used in the development of PROTACs (Proteolysis Targeting Chimeras) for targeted protein degradation. It acts as a linker-conjugated molecule, enabling the recruitment of E3 ubiquitin ligase to specific proteins of interest, leading to their ubiquitination and subsequent degradation by the proteasome. This application is particularly valuable in cancer research, where it helps in the selective elimination of disease-causing proteins. Additionally, it is utilized in the synthesis of antibody-drug conjugates (ADCs) to enhance the delivery of therapeutic agents to specific cells, improving treatment efficacy while minimizing off-target effects. Its PEG3 spacer improves solubility and stability, making it suitable for various biomedical applications.